Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead

Baird lowered its price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining an Outperform rating.

Analyst Michael Ulz notes building momentum with multiple commercial and clinical milestones in 2018.

"Notable catalysts remain on track for UX007, including potential for early filing in FAOD (update mid-2018) and Phase 3 data in Glut 1 DS movement (2H18)," he commented.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Raised to $20 at Morgan Stanley
• AutoZone (AZO) PT Lowered to $3,500 at Oppenheimer
• BMO Capital Downgrades Magna Intl (MG:CN) (MGA) to Market Perform